[HTML][HTML] Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY
AT Cohen, S Pan, W Byon, BS Ilyas, T Taylor… - Advances in Therapy, 2021 - Springer
Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …
[HTML][HTML] Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
AT Cohen, S Pan, W Byon, BS Ilyas, T Taylor… - Advances in …, 2021 - ncbi.nlm.nih.gov
Methods This post hoc analysis of the AMPLIFY trial evaluated the efficacy (venous
thromboembolism [VTE]/VTE-related death), safety (major and composite of major and …
thromboembolism [VTE]/VTE-related death), safety (major and composite of major and …
Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY.
AT Cohen, S Pan, W Byon, BS Ilyas, T Taylor… - Advances in …, 2021 - europepmc.org
Methods This post hoc analysis of the AMPLIFY trial evaluated the efficacy (venous
thromboembolism [VTE]/VTE-related death), safety (major and composite of major and …
thromboembolism [VTE]/VTE-related death), safety (major and composite of major and …
[PDF][PDF] Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
AT Cohen, SPW Byon, BSITT Theodore, C Lee - Adv Ther, 2021 - academia.edu
Introduction: As a result of limited clinical data, guidelines do not recommend the use of non-
vitaminK antagonist oral anticoagulants in patients who weigh [120 kg or have a body mass …
vitaminK antagonist oral anticoagulants in patients who weigh [120 kg or have a body mass …
Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
AT Cohen, S Pan, W Byon, BS Ilyas, T Taylor, TC Lee - 2021 - pubmed.ncbi.nlm.nih.gov
Introduction As a result of limited clinical data, guidelines do not recommend the use of non-
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …
vitamin K antagonist oral anticoagulants in patients who weigh> 120 kg or have a body …